NOW ENROLLING PHASE III sunRIZE TRIAL In the study of congenital hyperinsulinism

Learn More »
sunrize logo

Data Presentations

RZ402 Phase 2 Topline Data
rize-data-call-thumb
Phase 2b Data Presentation
/wp-content/uploads/2024/05/PES-2024-Poster-Rezolute-65-x-32-in-2.pdf
Pediatric Endocrine Society (PES) 2024 Annual Meeting
/wp-content/uploads/2024/05/PES-2024-Poster-Rezolute-65-x-32-in-2.pdf
An Analysis of Overnight Hypoglycemia in Patients with Congenital Hyperinsulinism:Results from the RZ358-606 (RIZE) StudyWhile 
RIZE Study results thumbnail
Phase 2b RIZE Data Presentation by Hüseyin Demirbilek, M.D. at ESPE 2022
Continuous-Glucose-Monitoring-(CGM)-Reveals-Undertreated-Hypoglycemia-in-Patients-with-Congenital-Hyperinsulinism-thumb
Continuous Glucose Monitoring (CGM) Reveals Undertreated Hypoglycemia in Patients with Congenital Hyperinsulinism
XOMA-358,-a-Novel-Treatment-for-Hyperinsulinemic-Hypoglycemia--Safety-and-Clinical-Pharmacology-from-the-First-in-Human-Trial-thumb
XOMA 358, a Novel Treatment for Hyperinsulinemic Hypoglycemia: Safety and Clinical Pharmacology from the First in Human Trial